Skip to main content
NewslettersWatchlist

Vir Biotechnology Inc(VIR-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low7.61
Day High8.00
Open:7.99
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
MarketBeat
From laggards to leaders: Small caps on the rise
BayStreet.ca
The Five Biotech Stocks Every Investor Should Know About
BayStreet.ca
A Potentially Revolutionary Tuberculosis Test Can Produce Results in 24 Hours
Motley Fool
Is Vir Biotechnology Stock a Buy?
Motley Fool
Why Shares of Vir Biotechnology Are Plunging Thursday
PR Newswire
Brii Biosciences Provides Latest Clinical Development and Corporate Updates
PR Newswire
Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023
Motley Fool
Why Shares of Keros Therapeutics Jumped This Week
PR Newswire
Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results
Barchart
Stocks Rise on Strength in Apple and Lower Bond Yields
Barchart
Markets Today: Stock Indexes Push Higher on Weaker Bond Yields
PR Newswire
Coronavirus Vaccine Market To Surpass $95 Billion By 2028
Barchart
Stocks Set To Open Lower As Investors Await FOMC Minutes
Motley Fool
2 Stocks That Could Turn $100 Into $1,000 by 2028
Motley Fool
2 Fast-Growing Healthcare Stocks to Buy and Hold
PR Newswire
Moore Kuehn, PLLC Encourages Investors of Vir Biotechnology, Inc. to Contact Law Firm
Motley Fool
Why Vir Biotechnology Jumped Nearly 19% Today
PR Newswire
Brii Biosciences Provides Corporate Update and Reports 2022 Interim Results
Globe Newswire
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Motley Fool
3 Fast-Growing Stocks to Buy Now
Motley Fool
2 Biotech Stocks That Could Help Make You a Fortune
Motley Fool
3 Cheap Stocks To Buy Now
PR Newswire
Brii Biosciences Exercises Option for Vir Biotechnology's VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B in Greater China
Globe Newswire
Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program
Motley Fool
Buy the Dip on These 3 Healthcare Stocks
Globe Newswire
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress™ 2022
Globe Newswire
Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details
Globe Newswire
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results
Globe Newswire
Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D Day
Globe Newswire
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial Results on May 5, 2022
InvestorPlace
4 Undervalued Biotech Stocks to Add to Your Buy List
Globe Newswire
Vir Biotechnology to Host a Virtual Hepatitis Portfolio R&D Day

Profile

Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. Vir Biotechnology Inc. is based in San Francisco, United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.